The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $141.31 billion in 2023 to $163.73 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to a heightened understanding of the significance of glycans, an increase in chronic diseases, the development of drugs for rare diseases, and collaborative efforts in glycomics research.
The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $301.03 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to the increasing understanding of glycan biology, the adoption of precision medicine approaches, growing interest in immunotherapy, higher funding for rare diseases research, and the emergence of glycan biomarkers. Major trends in the forecast period include the broader applications of glycomics in oncology, glycoengineering for improved therapeutic proteins, the integration of glycomics in immuno-oncology, the utilization of glycomics in rare and genetic disorders, and regulatory considerations for glycomic drugs.
The rise in the prevalence of diabetes is anticipated to boost the growth of the glycomic therapeutics market. Diabetes, a chronic medical condition affecting the regulation of blood sugar (glucose) levels, is associated with observed alterations in glycans, contributing to insulin resistance and other metabolic abnormalities. Distinct glycan patterns function as biomarkers for diagnosing diabetes, predicting its progression, and monitoring responses to treatment. For instance, as of May 2023, according to a report from the National Center for Health Statistics, the percentage of diagnosed diabetes in adults aged 18 and over in the United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the growth of glycomic therapeutics is driven by the increasing prevalence of diabetes.
The rising incidence of cancer is poised to drive the growth of the glycomic therapeutics market. Cancer, characterized by uncontrolled cell growth and spread, sees applications of glycomic therapeutics in treatment. These therapeutics target and modify specific sugar molecules on cell surfaces, influencing crucial cellular interactions, signaling pathways, and immune responses, with the goal of inhibiting tumor growth and enhancing the effectiveness of cancer therapies. For example, in 2023, the estimated number of new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, as reported by the American Cancer Society. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the glycomic therapeutics market.
Product innovation stands out as a prominent trend gaining traction in the glycomic therapeutics market. Key players in the glycomic therapeutics sector are strategically investing in the development of cutting-edge technologies and innovative solutions to fortify their market position. For example, in April 2022, Glenmark Pharmaceuticals Limited, an Indian-based pharmaceutical company dedicated to discovering advanced therapies, introduced a novel fixed-dose combination (FDC) featuring a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This innovative combination aims to enhance glycemic control and reduce insulin resistance in patients with type 2 diabetes.
Leading companies in the glycomic therapeutics sector are actively engaged in the creation of groundbreaking technological solutions, such as screening kits, to advance glycobiology research and exploration. A screening kit is a pre-packaged set of tools and materials designed for a preliminary test to detect the presence or absence of a specific substance, condition, or property. For instance, in July 2022, Vector Laboratories, a US-based provider of glycomic solutions, launched Glysite Scout Glycan screening kits. These kits, fully integrated for immunofluorescence, facilitate the detection of glycan expression in tissue sections, allowing researchers to profile and characterize complex glycans in biological systems and identify major surface glycan motifs in a sample.
In May 2022, Halozyme Therapeutics, a US-based biotechnology company, completed the acquisition of Antares Pharma Inc. for $960 million. This strategic move bolstered Halozyme's pipeline portfolio of novel treatments utilizing advanced drug delivery methods, enhancing safety, efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc. is a US-based pharmaceutical firm.
Major companies operating in the glycomic therapeutics market report are F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline PLC, Merck KGaA, ICON PLC, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd., Z Biotech LLC, Alzheon Inc., GlycoMar Limited.
North America was the largest region in the glycomic therapeutics in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of glycomic therapeutics fall into two classes isolated and synthetic. Isolated glycomic therapy focuses on the study and analysis of glycans in isolation, delving into the structural and functional characterization of individual glycan molecules. Synthetic glycomic therapy involves the use of artificially created glycans or glycan-based molecules for diagnosing and treating various diseases or medical conditions. These therapies target different structures such as glycoproteins, sialic acid, proteoglycans, glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans, glycosphingolipids, and others. The mode of action varies, including inhibiting neuraminidase, heparanase, selectins, blocking interactions between growth factors and heparan sulfate, and applications in erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, and targeting interleukins, interferons, among others. These therapies are employed for indications such as thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher’s disease, MPS-1 and IV, cancer, Alzheimer's disease, influenza types A and B, and more.
The glycomic therapeutics market research report is one of a series of new reports that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $301.03 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to the increasing understanding of glycan biology, the adoption of precision medicine approaches, growing interest in immunotherapy, higher funding for rare diseases research, and the emergence of glycan biomarkers. Major trends in the forecast period include the broader applications of glycomics in oncology, glycoengineering for improved therapeutic proteins, the integration of glycomics in immuno-oncology, the utilization of glycomics in rare and genetic disorders, and regulatory considerations for glycomic drugs.
The rise in the prevalence of diabetes is anticipated to boost the growth of the glycomic therapeutics market. Diabetes, a chronic medical condition affecting the regulation of blood sugar (glucose) levels, is associated with observed alterations in glycans, contributing to insulin resistance and other metabolic abnormalities. Distinct glycan patterns function as biomarkers for diagnosing diabetes, predicting its progression, and monitoring responses to treatment. For instance, as of May 2023, according to a report from the National Center for Health Statistics, the percentage of diagnosed diabetes in adults aged 18 and over in the United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the growth of glycomic therapeutics is driven by the increasing prevalence of diabetes.
The rising incidence of cancer is poised to drive the growth of the glycomic therapeutics market. Cancer, characterized by uncontrolled cell growth and spread, sees applications of glycomic therapeutics in treatment. These therapeutics target and modify specific sugar molecules on cell surfaces, influencing crucial cellular interactions, signaling pathways, and immune responses, with the goal of inhibiting tumor growth and enhancing the effectiveness of cancer therapies. For example, in 2023, the estimated number of new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, as reported by the American Cancer Society. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the glycomic therapeutics market.
Product innovation stands out as a prominent trend gaining traction in the glycomic therapeutics market. Key players in the glycomic therapeutics sector are strategically investing in the development of cutting-edge technologies and innovative solutions to fortify their market position. For example, in April 2022, Glenmark Pharmaceuticals Limited, an Indian-based pharmaceutical company dedicated to discovering advanced therapies, introduced a novel fixed-dose combination (FDC) featuring a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This innovative combination aims to enhance glycemic control and reduce insulin resistance in patients with type 2 diabetes.
Leading companies in the glycomic therapeutics sector are actively engaged in the creation of groundbreaking technological solutions, such as screening kits, to advance glycobiology research and exploration. A screening kit is a pre-packaged set of tools and materials designed for a preliminary test to detect the presence or absence of a specific substance, condition, or property. For instance, in July 2022, Vector Laboratories, a US-based provider of glycomic solutions, launched Glysite Scout Glycan screening kits. These kits, fully integrated for immunofluorescence, facilitate the detection of glycan expression in tissue sections, allowing researchers to profile and characterize complex glycans in biological systems and identify major surface glycan motifs in a sample.
In May 2022, Halozyme Therapeutics, a US-based biotechnology company, completed the acquisition of Antares Pharma Inc. for $960 million. This strategic move bolstered Halozyme's pipeline portfolio of novel treatments utilizing advanced drug delivery methods, enhancing safety, efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc. is a US-based pharmaceutical firm.
Major companies operating in the glycomic therapeutics market report are F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline PLC, Merck KGaA, ICON PLC, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd., Z Biotech LLC, Alzheon Inc., GlycoMar Limited.
North America was the largest region in the glycomic therapeutics in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of glycomic therapeutics fall into two classes isolated and synthetic. Isolated glycomic therapy focuses on the study and analysis of glycans in isolation, delving into the structural and functional characterization of individual glycan molecules. Synthetic glycomic therapy involves the use of artificially created glycans or glycan-based molecules for diagnosing and treating various diseases or medical conditions. These therapies target different structures such as glycoproteins, sialic acid, proteoglycans, glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans, glycosphingolipids, and others. The mode of action varies, including inhibiting neuraminidase, heparanase, selectins, blocking interactions between growth factors and heparan sulfate, and applications in erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, and targeting interleukins, interferons, among others. These therapies are employed for indications such as thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher’s disease, MPS-1 and IV, cancer, Alzheimer's disease, influenza types A and B, and more.
The glycomic therapeutics market research report is one of a series of new reports that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary2. Glycomic Therapeutics Market Characteristics3. Glycomic Therapeutics Market Trends and Strategies32. Global Glycomic Therapeutics Market Competitive Benchmarking33. Global Glycomic Therapeutics Market Competitive Dashboard34. Key Mergers and Acquisitions in the Glycomic Therapeutics Market
4. Glycomic Therapeutics Market - Macro Economic Scenario
5. Global Glycomic Therapeutics Market Size and Growth
6. Glycomic Therapeutics Market Segmentation
7. Glycomic Therapeutics Market Regional and Country Analysis
8. Asia-Pacific Glycomic Therapeutics Market
9. China Glycomic Therapeutics Market
10. India Glycomic Therapeutics Market
11. Japan Glycomic Therapeutics Market
12. Australia Glycomic Therapeutics Market
13. Indonesia Glycomic Therapeutics Market
14. South Korea Glycomic Therapeutics Market
15. Western Europe Glycomic Therapeutics Market
16. UK Glycomic Therapeutics Market
17. Germany Glycomic Therapeutics Market
18. France Glycomic Therapeutics Market
19. Italy Glycomic Therapeutics Market
20. Spain Glycomic Therapeutics Market
21. Eastern Europe Glycomic Therapeutics Market
22. Russia Glycomic Therapeutics Market
23. North America Glycomic Therapeutics Market
24. USA Glycomic Therapeutics Market
25. Canada Glycomic Therapeutics Market
26. South America Glycomic Therapeutics Market
27. Brazil Glycomic Therapeutics Market
28. Middle East Glycomic Therapeutics Market
29. Africa Glycomic Therapeutics Market
30. Glycomic Therapeutics Market Competitive Landscape and Company Profiles
31. Glycomic Therapeutics Market Other Major and Innovative Companies
35. Glycomic Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Glycomic Therapeutics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on glycomic therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glycomic therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Class: Isolated; Synthetic
2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans; Targeting Glycosphingolipids; Other Structures
3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin and Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 and 3; Beta and Gamma Interferons; Other Mode Of Action
4) By Indications: Thrombosis and Chemoprophylaxis; Anemia; Anti-Adhesive and Anti-Inflammatory; Cataracts; Gaucher’s Disease; Mps-1 and IV; Cancer; Alzheimer’s Disease; Influenza Type A and B; Other Indications
Key Companies Mentioned: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F Hoffmann-La Roche Ltd.
- Bayer AG
- Sanofi SA
- Thermo Fisher Scientific Inc.
- GlaxoSmithKline plc
- Merck KGaA
- ICON plc
- Agilent Technologies Inc.
- AMS Bio
- Shimadzu Corporation
- Waters Corporation
- Bruker Corporation
- BioMarin Pharmaceutical Inc.
- Bio Techne Corp.
- Promega Corporation
- Halozyme Therapeutics Inc.
- Takara Bio Inc.
- Vector Laboratories
- New England Biolabs Inc.
- Protalix Biotherapeutics Inc.
- Genovis AB
- Ray Biotech Life Inc.
- IEC Group
- Ludger Ltd
- Z Biotech LLC
- Alzheon Inc.
- GlycoMar Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 163.73 Billion |
| Forecasted Market Value ( USD | $ 301.03 Billion |
| Compound Annual Growth Rate | 16.4% |
| Regions Covered | Global |
